ASCO GUIDELINES Bundle

Lung Cancer Surveillance After Definitive Curative-Intent Therapy

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475471

Contents of this Issue

Navigation

Page 1 of 3

Key Points ➤ Although patients with localized non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) are treated with intent to cure, the optimal surveillance of these patients for cancer recurrence and new primary lung cancers after potentially curative therapy is controversial. Non-Small Cell Lung Cancer ➤ The chance of NSCLC recurrence is greatest during the first 2 years following treatment with curative intent. • Patients with an intrathoracic recurrence may be salvaged with surgical resection, stereotactic body radiotherapy (SBRT) or chemoradiation depending on the clinical scenario. • Early identification of extra-thoracic metastatic recurrence may allow prompt molecular testing and facilitate the safe administration of precision palliative therapy before patients develop severe symptoms or deteriorate. ➤ Two or more years after curative intent therapy, patients are at higher risk of developing a second primary lung cancer (1.5-2% per year) and may benefit from screening. Small Cell Lung Cancer ➤ During the first year after initial chemoradiation for SCLC, approximately 40% of patients with stage I-III (limited stage) will relapse. This increases to 60% during the 3 years post-treatment. • The risk of intracranial recurrence is significant. Therefore, close central nervous system (CNS) surveillance may afford treatment before permanent neurologic sequelae develop from symptomatic SCLC brain metastases. Recommendations NOTE: • These recommendations apply to patients with curatively treated stage I-III NSCLC and SCLC with no clinical suspicion of recurrent disease. This includes patients treated with surgery, stereotactic body radiotherapy and chemoradiation. Please refer to the recommendation discussion section for further details on specific patient subpopulations. • These recommendations pertain only to routine surveillance strategies. Imaging to evaluate symptoms and follow-up on previous findings are not addressed by this guideline. • These recommendations do not address the frequency of the clinical evaluation (history and physical exam) for either the suspicion of recurrence and/or to provide reassurance.

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Lung Cancer Surveillance After Definitive Curative-Intent Therapy